CureusMar 30, 2026

Why Weight Comes Back After Stopping GLP-1 Therapy: Treatment Failure, Body Responses, or Lack of Follow-Up

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 31, 2026

Abstract

Discontinuation of GLP-1-based therapy is associated with rapid weight regain within one year.

Randomized withdrawal trials demonstrate that stopping GLP-1 receptor agonists leads to a significant weight regain.
The observed weight regain is not a sign of treatment failure but rather a recurrence of obesity as a chronic condition.
Homeostatic weight-defense mechanisms return after therapy cessation, promoting a shift back to pre-treatment weight levels.
Sarcopenic obesity may occur post-discontinuation, characterized by a relative recovery of fat mass compared to lean mass.
Mitigation strategies such as resistance training and structured tapering could help manage weight regain after therapy ends.

Simplified

The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists targeting both the GIP and GLP-1 receptors (GIP/GLP-1 dual agonists) has reshaped obesity management, approaching degrees of weight loss previously achievable largely through metabolic surgery. However, randomized withdrawal trials, including Semaglutide Treatment Effect in People with Obesity (STEP) 4 and SURMOUNT 4, show that discontinuation of GLP-1-based therapy is consistently followed by rapid weight regain (typically observed within one year of withdrawal) and a decline in cardiometabolic benefits. Rather than indicating therapeutic failure, this pattern is best understood as disease recurrence, reinforcing obesity as a chronic, relapsing condition. After treatment is discontinued, homeostatic weight-defense mechanisms re-emerge, favoring a return toward the pre-treatment set point. This editorial examines the biology underpinning post-discontinuation weight regain and highlights a clinically underappreciated consequence: sarcopenic obesity, driven by preferential fat mass recovery relative to lean mass. It also discusses mitigation strategies, including resistance training and structured tapering approaches, and argues for long-term, maintenance-oriented care as an ethical imperative in chronic obesity management.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

PubMed

Why Weight Comes Back After Stopping GLP-1 Therapy: Treatment Failure, Body Responses, or Lack of Follow-Up

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief